A Glutamine Insertion at Codon 432 of RpoB Confers Rifampicin Resistance in Mycobacterium tuberculosis

Li-Yin Lai, Li-Yu Hsu, Shang-Hui Weng, Shuo-En Chung, Hui-En Ke, Tzu‐Lung Lin, Pei‐Fang Hsieh, Wei-Ting Lee, Hsing-Yuan Tsai, Wan-Hsuan Lin, Ruwen Jou, Jann‐Tay WangFrontiers in Microbiology 2020 · DOI

TL;DR

This paper identifies a novel mutation, a glutamine insertion at codon 432 (Q432insQ) in the rpoB gene, as a direct cause of rifampicin resistance in Mycobacterium tuberculosis. This finding is crucial for understanding and potentially diagnosing drug-resistant tuberculosis, a major global health threat.

What Problem Does This Paper Address?

Tuberculosis (TB) remains a leading cause of death worldwide, and its treatment is complicated by the emergence of drug-resistant strains. Rifampicin (RIF) is a cornerstone of first-line TB therapy, but resistance to this drug significantly hinders treatment success and increases the risk of transmission. While many mutations in the rpoB gene, particularly within the Rifampicin Resistance-Determining Region (RRDR), are known to confer RIF resistance, there's a continuous need to identify novel mutations. This is essential for improving diagnostic tools and understanding the full spectrum of resistance mechanisms, especially as some RIF-resistant strains exhibit resistance that isn't fully explained by known mutations. This study aims to uncover new rpoB mutations associated with high-level RIF resistance in clinical isolates.

Methods

The researchers employed a multi-pronged approach:

  • Sequencing of Clinical Isolates: They sequenced the rpoB gene from four RIF-resistant clinical isolates (CDC-1, CDC-2, CDC-3, and CDC-4) to identify novel mutations.
  • Plasmid Complementation: To test the functional impact of identified mutations, they created plasmids expressing mutant versions of the RpoB protein. These plasmids were then introduced into the well-characterized, susceptible Mycobacterium tuberculosis H37Rv reference strain. The minimum inhibitory concentration (MIC) of RIF was then determined for these transformed strains.
  • Site-Directed Mutagenesis and Homologous Recombination: For the most promising mutation (Q432insQ), they generated unmarked replacement mutants in the H37Rv strain using homologous recombination. This method precisely integrates the mutation into the bacterial chromosome, providing a more definitive assessment of its role in resistance.
  • Microplate Alamar Blue Assays (MABAs): This was the primary method used for determining RIF susceptibility (MIC) in various strains and transformants. It involves culturing bacteria in the presence of different RIF concentrations and observing growth.
  • Sensititre™ Mycobacterium tuberculosis MIC Plate: This was used for initial characterization of RIF resistance levels in the clinical isolates.

Datasets

The study utilized the following:

  • Clinical Isolates: Four RIF-resistant Mycobacterium tuberculosis isolates (CDC-1, CDC-2, CDC-3, and CDC-4) obtained from the Taiwan Centers for Disease Control.
  • Reference Strain: Mycobacterium tuberculosis H37Rv, a well-established laboratory strain.
  • Plasmid Constructs: Various rpoB expression plasmids (pMN437-derived and pGOAL19-derived) carrying wild-type or mutant rpoB genes.

No new benchmark datasets were introduced.

Key Insights and Ideas

  • Beyond the Usual Suspects: While mutations in the RRDR are well-established drivers of RIF resistance, this study highlights that novel mutations, even insertions, can also confer significant resistance.
  • Q432insQ is a Direct Driver of Resistance: The most significant finding is that the insertion of a glutamine at codon 432 (Q432insQ) in RpoB is sufficient to cause high-level RIF resistance in M. tuberculosis. This is a direct causal link, confirmed through multiple experimental approaches.
  • Other Mutations are Less Impactful (in isolation): The study suggests that other identified mutations (G158R, V168A, S188P) in these clinical isolates, when tested individually, do not significantly contribute to RIF resistance. This implies that the resistance observed in strains carrying these mutations might be due to other factors or synergistic effects not fully captured in this study.
  • Potential for Diagnostic Expansion: Identifying Q432insQ as a resistance-conferring mutation expands the repertoire of genetic markers that can be used for rapid molecular diagnostics of RIF-resistant TB.

Key Results

  • Four clinical isolates (CDC-1, CDC-2, CDC-3, CDC-4) exhibited high-level RIF resistance (MICs ranging from 8 to >16 mg/L).
  • Sequencing revealed unique rpoB mutations in these isolates, including G158R & V170F (CDC-1), V168A & V170F (CDC-2), V170F & S188P (CDC-3), and S431G & Q432insQ (CDC-4).
  • Plasmid complementation experiments showed that RpoB G158R, V168A, and S188P mutations did not increase the RIF MIC in the H37Rv strain.
  • However, introducing RpoB Q432insQ (either via plasmid or chromosomal replacement) into H37Rv significantly increased the RIF MIC, conferring resistance (MICs of 64-128 mg/L for plasmid and >1 mg/L for chromosomal mutants).
  • The combined mutation S431G plus Q432insQ in CDC-4 resulted in a two-fold higher MIC compared to Q432insQ alone, suggesting potential additive effects.

Limitations and Future Work

  • Limited Scope of Sequencing: The study focused solely on the rpoB gene. The high RIF resistance observed in strain CDC-2, which was not fully explained by the identified rpoB mutations, suggests the presence of other resistance mechanisms (e.g., antibiotic efflux pumps, porin alterations, or mutations in other genes) that were not investigated.
  • Slow Growth of CDC-4: The observation that the CDC-4 strain grew slower than H37Rv might influence the interpretation of resistance levels and suggests potential fitness costs associated with certain mutations.
  • Future Directions: The authors imply that further research into resistance mechanisms beyond rpoB is warranted. Expanding the repertoire of known resistance-conferring mutations is crucial for developing more comprehensive and accurate molecular diagnostic tools for TB. Investigating the synergistic effects of multiple mutations and exploring fitness costs associated with resistance mutations are also important avenues for future research.

Summary updated

Abstract

Tuberculosis (TB) is an infectious respiratory disease caused by <i>Mycobacterium tuberculosis</i> and one of the top 10 causes of death worldwide. Treating TB is challenging; successful treatment requires a long course of multiple antibiotics. Rifampicin (RIF) is a first-line drug for treating TB, and the development of RIF-resistant <i>M. tuberculosis</i> makes treatment even more difficult. To determine the mechanism of RIF resistance in these strains, we searched for novel mutations by sequencing. Four isolates, CDC-1, CDC-2, CDC-3, and CDC-4, had high-level RIF resistance and unique mutations encoding RpoB G<sup>158</sup>R, RpoB V<sup>168</sup>A, RpoB S<sup>188</sup>P, and RpoB Q<sup>432</sup>insQ, respectively. To evaluate their correlation with RIF resistance, plasmids carrying <i>rpoB</i> genes encoding these mutant proteins were transfected into the H<sub>37</sub>Rv reference strain. The plasmid complementation of RpoB indicated that G<sup>158</sup>R, V<sup>168</sup>A, and S<sup>188</sup>P did not affect the MIC of RIF. However, the MIC of RIF was increased in H<sub>37</sub>Rv carrying RpoB Q<sup>432</sup>insQ. To confirm the correlation between RIF resistance and Q<sup>432</sup>insQ, we cloned an <i>rpoB</i> fragment carrying the insertion (encoding RpoB Q<sup>432</sup>insQ) into H<sub>37</sub>Rv by homologous recombination using a suicide vector. All replacement mutants expressing RpoB Q<sup>432</sup>insQ were resistant to RIF (MIC > 1 mg/L). These results indicate that RpoB Q<sup>432</sup>insQ causes RIF resistance in <i>M. tuberculosis</i>.
BibTeX
@inproceedings{lai2020glutamine,
  author = {Li-Yin Lai and Li-Yu Hsu and Shang-Hui Weng and Shuo-En Chung and Hui-En Ke and Tzu‐Lung Lin and Pei‐Fang Hsieh and Wei-Ting Lee and Hsing-Yuan Tsai and Wan-Hsuan Lin and Ruwen Jou and Jann‐Tay Wang},
  title = {{A Glutamine Insertion at Codon 432 of RpoB Confers Rifampicin Resistance in Mycobacterium tuberculosis}},
  booktitle = {Frontiers in Microbiology},
  year = {2020},
  doi = {10.3389/fmicb.2020.583194},
}
Figure